Press Release titled Quaterly Earnings Release dated August 08, 2026

August 08, 2026 BSE Limited National Stock Exchange of India Limited P. J. Towers, Exchange Plaza, Plot No. C/1, Dalal Street, G Block, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E) Mumbai- 400 051 Scrip Code-540025 Trading Symbol-ADVENZYMES Subject: Press Release Ref: ISIN: INE837H01020 Dear Sir/Madam, Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is Press Release, titled "Quarterly Earnings Release” dated August 08, 2026. This is for your information and for public at large. Thanking you, Yours faithfully, For Advanced Enzyme Technologies Limited Sanjay Basantani Company Secretary and Head – Legal Encl.: As above FOR IMMEDIATE RELEASE QUARTERLY EARNINGS RELEASE Thane, India: Saturday, August 08, 2026 Advanced Enzyme Technologies Limited announces Financial Results for First Quarter ended June 2026 Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes, today announced their unaudited financial results for first quarter ended June 2026. CONSOLIDATED QUARTERLY FINANCIAL HIGHLIGHTS: Q1 Q4 Q1 Change Change Change (Amount in INR Mn.) FY26 FY25 FY27 FY26 FY26 (Y-o-Y %) (Q-o-Q %) (%) Revenue 1,898 2,034 1,859 +2% -7% 7,458 6,369 +17% EBITDA 510 632 564 -10% -19% 2,291 1,944 +18% EBITDA Margin (%) 27% 31% 30% 31% 31% PAT 386 453 404 -5% -15% 1,736 1,340 +30% PAT Margin (%) 20% 22% 22% 23% 21% EPS 3.31 3.84 3.57 -7% -14% 15.08 11.72 +29% CONSOLIDATED FINANCIAL REVIEW (Y-o-Y basis): Revenue from Operations: Margin: Revenue from operations on consolidated basis EBITDA margin stands at 27%, PBT margin stands increased to ₹ 1,898 million in Q1 FY27 from ₹ at 28% and PAT margin stands at 20% during the 1,859 million in Q1 FY26, a growth of 2%. quarter. Profit: Financial Costs: Consolidated EBITDA during Q1 FY27 stands at Financial costs stood at ₹ 6 million during Q1 FY27 ₹ 510 million as compared to ₹ 564 million during as against ₹ 8 million in Q1 FY26. Q1 FY26, decreased by 10%. Depreciation and Amortization: Profit before tax stands at ₹ 535 million during Q1 Depreciation and Amortization charge for Q1 FY27 as against ₹ 549 million in Q1 FY26, FY27 stood at ₹ 99 million as compared to ₹ 96 decreased by 3%. million in the same quarter previous year. Profit after tax de-grew by 5% and stands at ₹ 386 Earnings Per Share: million during Q1 FY27 as compared to ₹ 404 Earnings Per Share during Q1 FY27 stands at million during Q1 FY26. ₹ 3.31 as compared to ₹ 3.57 in Q1 FY26. www.advancedenzymes.com 1 OPERATIONAL PERFORMANCE REVIEW: Segmental Revenue: Human Nutrition Q1 Q1 Change (Amount in INR Mn.) FY27 FY26 (%) 16% Animal Nutrition Human Nutrition 1,139 1,221 -7% Bio-Processing Animal Nutrition 252 260 -3% 13% Specialized Manufacturing Bio-Processing 306 236 +30% Specialized Manufacturing 200 142 +41% The total revenue from operations grew by 2% on The Bio-Processing segment delivered a strong y-o-y basis and de-grew by 7% on q-o-q basis. performance during the quarter, with revenue increasing by 30% year-on-year to ₹306 million in Revenue from the Human Nutrition segment Q1 FY27 from ₹236 million in Q1 FY26. Within the declined by 7% y-o-y to ₹1,139 million in Q1 FY27, segment, the Food business registered robust compared with ₹1,221 million in Q1 FY26. The growth of 51% y-o-y, reaching ₹263 million in Q1 decline was primarily attributable to lower sales in FY27. In contrast, the Non-Food business declined the Pharma/API business. by 30% y-o-y to ₹43 million during the quarter. The Animal Nutrition segment reported a 3% y-o-y The Specialized Manufacturing segment decline in revenue to ₹252 million in Q1 FY27, contributed 11% to the Company's total revenue compared with ₹260 million in Q1 FY26. during the quarter, with revenue increasing by 41% y-o-y to ₹200 million. Geographical Revenue: 2% Domestic sales accounted for ₹ 937 million in Q1 FY27 as compared to ₹ 979 million in Q1 FY26, India lower by 4%. Americas The total revenue comprises of International 49% Europe sales amounting to ₹ 961 million in Q1 FY27 as Asia (ex-India) compared to ₹ 881 million in Q1 FY26, an 29% Rest of the world increase of 9%. The revenue declined by 3% in Americas and 15% in the rest of the world while registered a growth of 44% in Europe, 37% in Asia (ex-India). The domestic sales constituted about 49% of revenue from operations during Q1 FY27 as compared to 53% during Q1 FY26. International sales were 51% of revenue from operations during Q1 FY27 as compared to 47% during Q1 FY26. www.advancedenzymes.com 2 CONSOLIDATED FINANCIAL REVIEW (Q-o-Q basis): Revenue from Operations: ₹ 453 million during Q4 FY26. Revenue from operations on consolidated basis decreased to ₹ 1,898 million in Q1 FY27 from Financial Costs: ₹ 2,034 million in Q4 FY26, a de-growth of 7%. Financial costs remain unchanged and stood at ₹ 6 million during Q1 FY27 as compared to last Profit: quarter. Consolidated EBITDA during Q1 FY27 stands at ₹ 510 million as compared to ₹ 632 million during Depreciation and Amortization: Q4 FY26, lower by 19%. Depreciation and Amortization charge for Q1 FY27 is ₹ 99 million as compared to ₹ 102 million Profit before tax stands at ₹ 535 million during Q1 in the last quarter. FY27 as against ₹ 598 million in Q4 FY26, decreased by 10% Earnings Per Share: Earnings Per Share during Q1 FY27 stands at Profit after tax de-grew by 15% and stands at ₹ 3.31 as compared to ₹ 3.84 in Q4 FY26. ₹ 386 million during Q1 FY27 as compared to OPERATIONAL PERFORMANCE REVIEW: Segmental Revenue: The Animal nutrition grew by 1% to ₹ 252 million in Q1 Q4 Change (Amount in INR Mn.) Q1 FY27 as against ₹ 250 million in Q4 FY26. FY27 FY26 (%) Human Nutrition 1,139 1,281 -11% The Bio-Processing segment recorded a 5% quarter-on-quarter decline in revenue to ₹306 Animal Nutrition 252 250 +1% million in Q1 FY27 from ₹324 million in Q4 FY26. Bio-Processing 306 324 -5% Within the segment, the Food business declined by 5% quarter-on-quarter to ₹263 million, while the Specialized Manufacturing 200 180 +11% Non-Food business registered an 8% q-o-q decrease to ₹43 million. The human nutrition segment reflected a de- growth 11% to ₹ 1,139 million in Q1 FY27 as The Specialized manufacturing segment compared to ₹ 1,281 million in Q4 FY26. registered a growth of 11% to ₹ 200 million in Q1 FY27 from ₹ 180 million in Q4 FY26. Geographical Revenue: Domestic sales accounted for ₹ 937 million in Q1 Americas, 3% in Asia (ex-India) and 29% in rest of FY26 as compared to ₹ 1,061 million in Q4 FY26, a the world while registered a growth of 39% in de-growth of 12%. The domestic sales constituted Europe. about 49% of revenue from operations during Q1 FY27 as compared to 52% during Q4 FY26. International sales were 51% of revenue from operations during Q1 FY27 as compared to 48% The total revenue comprises of International sales during Q4 FY26. amounting to ₹ 961 million in Q1 FY27 as compared to ₹ 973 million in Q4 FY26, marginal decline of 1%. The revenue de-grew by 5% in www.advancedenzymes.com 3 OUTLOOK 2026-27 Advanced Enzymes remains committed to Nutrition segment, it is committed to launching new enhancing and strengthening its business model by products aimed at boosting immunity, improving maintaining a strong focus across its three key digestion, and enhancing the nutritional value of segments—Human Nutrition, Animal Nutrition, and animal feed. Bio-Processing. The company is actively working on expanding its product portfolio, particularly in the Bio Catalysis: probiotics space, through ongoing development and The Company has achieved notable progress in new product launches. With its current infrastructure developing biocatalysis for API manufacturers, and capital investments, Advanced Enzymes is well- offering targeted enzymatic solutions that help positioned to grow its enzymes and probiotics reduce energy [Showing first 8,000 characters — download PDF for full document]